USANA Health Sciences (USNA) Misses Q3 EPS by 14c; Lowers FY Outlook

USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $0.78, $0.14 worse than the analyst estimate of $0.92. Revenue for the quarter came in at $233 million versus the consensus estimate of $245.95 million.

GUIDANCE:

USANA Health Sciences sees FY2022 EPS of $3.15-$3.40, versus the consensus of $3.90. USANA Health Sciences sees FY2022 revenue of $0.955-0.975 billion, versus the consensus of $1.03 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform